Biomaterial-based ocular drug delivery: strategies, challenges, and future perspectives
Source abstract
Abstract
Traditional ocular drug delivery methods suffer from low bioavailability, short precorneal residence time, and poor patient adherence due to ocular physiological and anatomical barriers. This review systematically summarizes biomaterial-based platforms for ocular drug delivery, focusing on controlled release, targeting, permeability, and synergistic therapy. The review also discusses key clinical features of ocular disorders, including dry eye disease, infectious keratitis, glaucoma, and age-related macular degeneration. It also evaluates the therapeutic performance and clinical translation of key systems, and identifies current challenges and future directions. This paper aims to provide theoretical foundations and innovative approaches for developing more efficient and safer ophthalmic drug delivery strategies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Corneal Surgery and Treatments · Ocular Disorders and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. The Lancet Global Health Commission on Global Eye Health: vision beyond 202010.1016/S2214-109X(20)30488-5 ↗
2. Age-related macular degeneration10.1016/S0140-6736(22)02609-5 ↗
3. Infectious Keratitis in 202110.1001/jama.2021.0424 ↗
4. The effect of insurance coverage laws on glaucoma eyedrop medication usage10.1016/j.ophtha.2023.12.022 ↗
5. Interactions of the choroid, Bruch's membrane, retinal pigment epithelium, and neurosensory retina collaborate to form the outer blood-retinal-barrier10.1016/j.preteyeres.2019.100803 ↗
6. Pharmacokinetic aspects of retinal drug delivery10.1016/j.preteyeres.2016.12.001 ↗
7. The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study10.1016/j.ophtha.2019.10.022 ↗
8. Antimicrobial resistance: a concise update10.1016/j.lanmic.2024.07.010 ↗
9. Severe intraocular inflammation following intravitreal faricimab10.1001/jamaophthalmol.2024.0530 ↗
10. Size‐evolving protein drug nanoparticles: a promising non‐invasive strategy for retinal neovascularization by overcoming multiple ocular barriers
11. A biomimetic peptide-drug supramolecular hydrogel as eyedrops enables controlled release of ophthalmic drugs10.1016/j.actbio.2023.06.036 ↗
12. Targeted noninvasive treatment of choroidal neovascularization by hybrid cell-membrane-cloaked biomimetic nanoparticles10.1021/acsnano.1c00680 ↗
13. Chitosan-poly(lactide-co-glycolide)/poloxamer mixed micelles as a mucoadhesive thermo-responsive moxifloxacin eye drop to improve treatment efficacy in bacterial keratitis10.1016/j.carbpol.2023.120822 ↗
14. Absorption enhancement strategies in chitosan-based nanosystems and hydrogels intended for ocular delivery: latest advances for optimization of drug permeation10.1016/j.carbpol.2024.122486 ↗
15. Insight on updates in polysaccharides for ocular drug delivery10.1016/j.carbpol.2022.120014 ↗
16. Responsive microneedles for diagnostic and therapeutic applications of ocular diseases10.1002/smtd.202402048 ↗
17. Recent advances in engineered exosome-based therapies for ocular vascular disease10.1186/s12951-025-03589-3 ↗
18. Microenvironment-triggered degradable hydrogel for imaging diagnosis and combined treatment of intraocular choroidal melanoma10.1021/acsnano.0c06000 ↗
19. Cell wall destruction and internal cascade synergistic antifungal strategy for fungal keratitis10.1021/acsnano.2c07444 ↗
20. Restoring light sensitivity using tunable near-infrared sensors10.1126/science.aaz5887 ↗
21. Liposome-based multifunctional nanoplatform as effective therapeutics for the treatment of retinoblastoma10.1016/j.apsb.2021.10.009 ↗
22. Exosome-loading miR-205: a two-pronged approach to ocular neovascularization therapy10.1186/s12951-024-03079-y ↗
23. Potential of vB_Pa_ZCPS1 phage embedded in situ gelling formulations as an ocular delivery system to attenuate Pseudomonas aeruginosa keratitis in a rabbit model10.1016/j.jconrel.2025.01.091 ↗
24. Microneedle-mediated biomimetic nanoparticles for targeted antioxidant and anti-inflammatory therapy in age-related macular degeneration10.1016/j.jconrel.2025.113908 ↗
25. Delivery of a novel neuroprotective compound to the retina in rat and rabbit animal models10.1016/j.jconrel.2025.113659 ↗
26. Customizable virus-like particles deliver CRISPR-Cas9 ribonucleoprotein for effective ocular neovascular and Huntington's disease gene therapy10.1038/s41565-024-01851-7 ↗
27. Ophthalmic drug delivery systems–recent advances10.1016/S1350-9462(97)00002-5 ↗
28. Drug Transport by the Blood–Aqueous Humor Barrier of the Eye10.1124/dmd.116.069369 ↗
29. An ocular glymphatic clearance system removes β-amyloid from the rodent eye10.1126/scitranslmed.aaw3210 ↗
30. Scleral structure and biomechanics10.1016/j.preteyeres.2019.100773 ↗
31. Wnt signaling activates MFSD2A to suppress vascular endothelial transcytosis and maintain blood-retinal barrier
32. TFOS DEWS II tear film report10.1016/j.jtos.2017.03.006 ↗
33. Primary open-angle glaucoma10.1038/nrdp.2016.67 ↗
34. Periocular routes for retinal drug delivery10.1517/17425247.1.1.99 ↗
35. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis10.1016/j.ophtha.2009.05.014 ↗
36. Glaucoma medical treatment: philosophy, principles and practice10.1038/eye.2000.138 ↗
37. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials10.1016/S0140-6736(22)00018-6 ↗
38. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration10.1016/j.ophtha.2019.12.031 ↗
39. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study10.1097/IAE.0b013e31827b6324 ↗
40. Defining nonadherence and nonpersistence to anti–vascular endothelial growth factor therapies in neovascular age-related macular degeneration10.1001/jamaophthalmol.2021.1660 ↗
41. Social and health care utilization factors associated with ophthalmic visit nonadherence in glaucoma: an all of us study10.1097/IJG.0000000000002300 ↗
42. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration10.1016/j.ophtha.2012.09.006 ↗
43. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab10.1016/j.ophtha.2020.04.017 ↗
44. Patient-reported complications after intravitreal injection and their predictive factors10.1016/j.oret.2020.09.024 ↗
45. Trans-corneal drug delivery strategies in the treatment of ocular diseases10.1016/j.addr.2023.114868 ↗
46. Prediction of the corneal permeability of drug-like compounds10.1007/s11095-010-0132-8 ↗
47. Penetration into the anterior chamber via the conjunctival/scleral pathway10.1089/jop.1997.13.41 ↗
48. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses10.1016/j.cis.2015.08.002 ↗
49. Adherence and persistence to medical therapy in glaucoma: an overview10.1007/s40123-023-00730-z ↗
50. Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics10.1016/j.preteyeres.2010.04.003 ↗
51. Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo10.1016/j.jconrel.2013.01.018 ↗
52. Biomaterials for orbital implants and ocular prostheses: overview and future prospects10.1016/j.actbio.2013.12.014 ↗
53. Peng C, Kuang L, Zhao J, et al., Bibliometric and visualized analysis of ocular drug delivery from 2001 to 2020, J Control Release, 345 (2022) 625-45. Doi: 10.1016/j.jconrel.2022.03.031.10.1016/j.jconrel.2022.03.031 ↗
54. ZIF-8-coated ZnO with pH-responsive natamycin release boosting the antifungal and anti-inflammation activity to treat fungal keratitis10.1039/D5TB00802F ↗
55. Antibiotic-free ocular sterilization while suppressing immune response to protect corneal transparency in infectious keratitis treatment10.1016/j.jconrel.2024.08.038 ↗
56. Mesoporous zinc oxide-based drug delivery system offers an antifungal and immunoregulatory strategy for treating keratitis10.1016/j.jconrel.2024.03.006 ↗
57. Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: a push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy10.1016/j.biomaterials.2020.119961 ↗
58. Harnessing the tunable cavity of nanoceria for enhancing Y-27632-mediated alleviation of ocular hypertension10.7150/thno.54525 ↗
59. MMP9-responsive graphene oxide quantum dot-based nano-in-micro drug delivery system for combinatorial therapy of choroidal neovascularization
60. ROS-responsive charge reversal mesoporous silica nanoparticles as promising drug delivery system for neovascular retinal diseases10.1016/j.jconrel.2024.07.022 ↗
61. Clickable corneal neovascularization therapy with ROS-responsive polydopamine silica nanoparticles loaded with fenofibrate10.1016/j.matdes.2023.112412 ↗
62. Maltodextrin-driven MOF Nano-antibacterial system for effective targeted bacteria and enhancing photodynamic therapy in bacterial keratitis10.1016/j.jconrel.2025.02.031 ↗
63. Bilayer hydrogel sheet-type intraocular microrobot for drug delivery and magnetic nanoparticles retrieval
64. Hybrid biomembrane-functionalized nanorobots penetrate the vitreous body of the eye for the treatment of retinal vein occlusion10.1021/acsnano.4c12327 ↗
65. Bipyramidal gold nanoparticles-assisted plasmonic photothermal therapy for ocular applications10.1039/D4TB02688H ↗
66. Antioxidant carbon dots nanozyme loaded in thermosensitive in situ hydrogel system for efficient dry eye disease treatment10.2147/IJN.S456613 ↗
67. Two-dimensional carbon graphdiyne: advances in fundamental and application research10.1021/acsnano.3c03849 ↗
68. Polymeric micelles as new drug carriers10.1016/S0169-409X(96)00401-2 ↗
69. Implementing polymeric pseudorotaxanes for boosting corneal permeability and antiaspergillus activity of tolnaftate: formulation development, statistical optimization, ex vivo permeation and in vivo assessment10.1080/10717544.2022.2094499 ↗
70. Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa®) for dry eye disease10.1007/s11095-018-2556-5 ↗
71. Highly effective corneal permeability of reactive oxygen species-responsive nano-formulation encapsulated cyclosporine a for dry eye management10.1016/j.cej.2023.143968 ↗
72. Active trans-corneal drug delivery with ocular adhesive micelles for efficient glaucoma therapy10.1016/j.jconrel.2024.11.050 ↗
73. The role of micelle size in tumor accumulation, penetration, and treatment10.1021/acsnano.5b02017 ↗
74. Enhanced ocular delivery of beva via ultra-small polymeric micelles for noninvasive anti-VEGF therapy
75. Recent advances with liposomes as pharmaceutical carriers10.1038/nrd1632 ↗
76. Design of liposomes as drug delivery system for therapeutic applications10.1016/j.ijpharm.2021.120571 ↗
77. Chitosan coated liposomes (CCL) containing triamcinolone acetonide for sustained delivery: a potential topical treatment for posterior segment diseases10.1016/j.ijbiomac.2019.10.256 ↗
78. In vivo fate of liposomes after subconjunctival ocular delivery10.1016/j.jconrel.2020.11.053 ↗
79. Targeted delivery of herpes simplex virus glycoprotein D to CD169(+) macrophages using ganglioside liposomes alleviates herpes simplex keratitis in mice10.1016/j.jconrel.2023.11.026 ↗
80. Engineered extracellular vesicles for delivery of an IL-1 receptor antagonist promote targeted repair of retinal degeneration
81. A novel, liposome-loaded, injectable hydrogel for enhanced treatment of choroidal neovascularization by sub-tenon's injection
82. Recent advances in surface-modified liposomes with polysaccharides for bioactive delivery10.1016/j.foodchem.2025.145580 ↗
83. Mucin-targeting-aptamer functionalized liposomes for delivery of cyclosporin a for dry eye diseases10.1039/D3TB00598D ↗
84. Mucoadhesive liposomal delivery system synergizing anti-inflammation and anti-oxidation for enhanced treatment against dry eye disease10.1016/j.jconrel.2024.02.043 ↗
85. Corneal mucin-targeting liposome nanoplatforms enable effective treatment of dry eye diseases by integrated regulation of ferroptosis and inflammation
86. Lipid-based nanocarriers challenging the ocular biological barriers: current paradigm and future perspectives10.1016/j.jconrel.2023.08.018 ↗
87. Trimethylated chitosan-coated flexible liposomes with resveratrol for topical drug delivery to reduce blue-light-induced retinal damage10.1016/j.ijbiomac.2023.126480 ↗
88. Dendritic oligoethylenimine decorated liposome with augmented corneal retention and permeation for efficient topical delivery of antiglaucoma drugs10.1021/acs.nanolett.3c03691 ↗
89. Cationic liposome-mediated scavenging of cell-free DNA: an innovative and alternative therapeutic approach for efficient treatment of dry eye disease
90. Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage10.1186/s12951-024-02503-7 ↗
91. Exosomes: composition, biogenesis and function10.1038/nri855 ↗
92. Exosomes in Cancer Nanomedicine and Immunotherapy: prospects and challenges10.1016/j.tibtech.2017.03.004 ↗
93. Exosomes-based dual drug-loaded nanocarrier for targeted and multiple proliferative vitreoretinopathy therapy10.1093/rb/rbae081 ↗
94. A synergistic therapeutic nano-eyedrop for dry eye disease based on ascorbic acid-coupled exosomes10.1039/D2NR05178H ↗
95. Injectable, antioxidative, and loaded with exosomes/Liproxstatin-1 hydrogel as a potential treatment for retinal ischemia–reperfusion by inhibiting ferroptosis and apoptosis10.1016/j.cej.2024.154509 ↗
96. Engineered mesenchymal stromal cell exosomes-loaded microneedles improve corneal healing after chemical injury10.1021/acsnano.4c00423 ↗
97. Functional engineered exosomes mitigate pathological ischemic retinopathy through a dual strategy of inflammatory microenvironment modulation and angiogenic factor control10.1016/j.matdes.2023.112240 ↗
98. Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone10.1038/s41551-019-0502-4 ↗
99. Membrane fusion-mediated loading of therapeutic sirna into exosome for tissue-specific application10.1002/adma.202403935 ↗
100. MiRNA 24-3p-rich exosomes functionalized DEGMA-modified hyaluronic acid hydrogels for corneal epithelial healing